Literature DB >> 15165832

Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network.

Olivier Pierrefiche1, Martine Daoust, Mickaël Naassila.   

Abstract

Acamprosate (calcium acetylhomotaurinate) has been shown to be effective in attenuating relapse in human alcoholics. The precise mechanism for acamprosate has been yet to be determined as there may be multiple sites of action for this drug. We investigated the mechanism of action of acamprosate on a spontaneous rhythmic activity recorded from hypoglossal nerve rootlet (XII) in neonatal rat brainstem slices. At 30 microM, acamprosate reversibly increased burst amplitude and reduced burst frequency, whereas at higher concentrations (100-400 microM) it induced a reversible and concentration-dependent inhibition of this activity. Interestingly, acamprosate (30 microM) enhanced the effects of low NMDA-induced excitation (1.5 microM), but inhibited higher NMDA-induced excitation (2.5, 5 microM) by 50-70%, demonstrating a differential effect on NMDA-induced excitation. Blockade of GABAA receptors did not affect the increase in amplitude of 30 microM acamprosate and partially abolished the inhibitory effects of 200 microM acamprosate. At 200 microM, acamprosate reduced high NMDA-induced excitation and abolished NMDA-evoked excitatory tonic phase, suggesting that excitatory effect of low concentrations of acamprosate mainly involved NMDA receptors, while the inhibitory effects at higher concentration included an increase in GABAA-mediated inhibition with a reduction of NMDA-mediated excitation. Consequently, combined blockade of both receptors abolished all effects of acamprosate tested at all concentrations. These results show that the effects of acamprosate are mediated via both GABAA and NMDA receptors and suggest a partial co-agonist role on NMDA receptors, at the level of a spontaneously active network.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165832     DOI: 10.1016/j.neuropharm.2004.03.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Authors:  Craig A Erickson; Logan K Wink; Balmiki Ray; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Debomoy K Lahiri; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

Review 3.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

4.  Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.

Authors:  Craig A Erickson; Logan K Wink; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2014-04

5.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

Review 6.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

Authors:  Craig A Erickson; Maureen Early; Kimberly A Stigler; Logan K Wink; Jennifer E Mullett; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-02       Impact factor: 2.576

Review 8.  [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].

Authors:  M Gahr; M A Kölle; C Schönfeldt-Lecuona
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

Review 9.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.